Elevated serum lipoprotein(a) as a potential predictor for combined intracranial and extracranial artery stenosis in patients with ischemic stroke

Kim, B.S.; Jung, Hwanseok; Bang, Oh Young; Chung, Chin‐Sang; Lee, K.H.; Kim, G.M.

doi:10.1016/j.atherosclerosis.2010.07.007

Cited by 54 publications

(36 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[31e38]; lack of control group (n ¼ 3) [28,39,40]; insufficient statistic data (reporting OR without 95% CI or lacking OR) (n ¼ 2) [29,41]; was included in the meta-analysis of 2006 (n ¼ 1) [30]; or partially overlapping study populations (n ¼ 3) [42e44].…”

Section: Search Resultsmentioning

confidence: 99%

Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysis

et al. 2015

View full text Add to dashboard Cite

Section: Search Resultsmentioning

confidence: 99%

Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysis

et al. 2015

View full text Add to dashboard Cite

“…Differing effects of LPA variants on individual stroke subtypes also may contribute to inconsistencies between the results of the HPS and some previous studies. 18 However, because the HPS is unable to assess the effects of LPA on different stroke subtypes, further studies are required to examine potentially variable effects of LPA on strokes of differing etiology. The HPS is a secondary prevention population of older individuals (mean age, 64 years) and, hence, has higher incident event rates than the general population.…”

Section: Hopewell Et Al Lpa Variants and Risk Of Vascular Diseasementioning

confidence: 99%

Lipoprotein(a) Genetic Variants Associated With Coronary and Peripheral Vascular Disease but Not With Stroke Risk in the Heart Protection Study

Hopewell

Clarke

Parish

et al. 2011

Circ Cardiovasc Genet

View full text Add to dashboard Cite

Background— Genetic studies have identified 2 single-nucleotide polymorphisms (SNPs) at the LPA locus (rs3798220 and rs10455872) that are strongly and independently related to lipoprotein(a) levels and to coronary disease risk, but their relevance for other atherothrombotic disease is uncertain. Methods and Results— These 2 LPA SNPs were examined together as an LPA genotype score for associations with vascular outcomes among participants in the Heart Protection Study. The LPA score was examined first in 12 236 participants with prevalent vascular disease (9277 coronary disease cases, and 1326 ischemic stroke and 2011 peripheral vascular disease cases with no history of coronary disease) and 3687 vascular disease-free controls and, subsequently, in 3251 participants who had incident major vascular events during follow-up (2106 coronary disease, 507 ischemic stroke, and 707 peripheral vascular disease events). For prevalent disease, the LPA score was strongly associated with coronary disease (odds ratio [OR] per variant allele, 1.19; 95% CI, 1.08 to 1.30) and peripheral vascular disease (OR, 1.18; 95% CI, 1.04 to 1.34) but not with ischemic stroke (OR, 1.03; 95% CI, 0.89 to 1.20). Similarly, for incident disease, the LPA score was strongly associated with coronary disease (hazard ratio [HR], 1.19; 95% CI, 1.09 to 1.30) and peripheral vascular disease (HR, 1.20; 95% CI, 1.02 to 1.40) but not with ischemic stroke (HR, 0.83; 95% CI, 0.67 to 1.03). Conclusions— The comparable strength of associations of the LPA score with coronary disease and peripheral vascular disease but not with stroke suggest that lipoprotein(a) may have effects on atherothrombotic vascular disease that are only relevant at specific sites. Clinical Trial Registration— URL: http://isrctn.org . Unique identifier: ISRCTN48489393.

show abstract

“…[11][12][13][14] The study of circulating biomarkers related to atherosclerosis is a good tool to assess its physiopathology in vivo. Few retrospective studies have evaluated inflammatory and metabolic markers associated with the different location (extra-versus intracranial) of cerebral atherosclerosis, [15][16][17][18] with only one study performed in asymptomatic subjects. 19 A proinflammatory state and an impaired fibrinolysis have also been associated with progression of symptomatic intracranial atherosclerosis.…”

mentioning

confidence: 99%

Biological Signatures of Asymptomatic Extra- and Intracranial Atherosclerosis

López‐Cancio

Galán²,

Dorado³

et al. 2012

Stroke

View full text Add to dashboard Cite

Background and Purpose-Intracranial atherosclerotic disease (ICAD) remains a challenge for stroke primary and secondary prevention. Molecular pathways involved in the development of ICAD from its asymptomatic stages are largely unknown. In our population-based study, we aimed to compare the risk factor and biomarker profiles associated with intracranial and extracranial asymptomatic cerebral atherosclerosis. Methods-The Asymptomatic Intracranial Atherosclerosis (AsIA) study cohort includes a random sample population of 933 white subjects Ͼ50 years with a moderate to high vascular risk (based on REGICOR score) and without a history of stroke (64% males; mean age, 66 years). Carotid and intracranial atherosclerosis were screened by cervical and transcranial color-coded Duplex ultrasound, being moderate to severe stenoses confirmed by MR angiography. We registered clinical and anthropometric data and created a biobank with blood samples at baseline. A panel of biomarkers involved in atherothrombogenesis was determined: C-reactive protein, asymmetric-dimethylarginine, resistin, and plasminogen activator inhibitor-1. Insulin resistance was quantified by Homeostasis Model Assessment index. Results-After multinomial regression analyses, male sex, hypertension, smoking, and alcoholic habits were independent risk factors of isolated extracranial atherosclerotic disease. Diabetes and metabolic syndrome conferred a higher risk for ICAD than for extracranial atherosclerotic disease. Moreover, metabolic syndrome and insulin resistance were independent risk factors of moderate to severe ICAD but were not risk factors of moderate to severe extracranial atherosclerotic disease. Regarding biomarkers, asymmetric-dimethylarginine was independently associated with isolated ICAD and resistin with combined ICAD-extracranial atherosclerotic disease. Conclusions-Our

show abstract

Elevated serum lipoprotein(a) as a potential predictor for combined intracranial and extracranial artery stenosis in patients with ischemic stroke

Cited by 54 publications

References 34 publications

Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysis

Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysis

Lipoprotein(a) Genetic Variants Associated With Coronary and Peripheral Vascular Disease but Not With Stroke Risk in the Heart Protection Study

Biological Signatures of Asymptomatic Extra- and Intracranial Atherosclerosis

Contact Info

Product

Resources

About